Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UHUMZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IBI-354
|
|||||
| Synonyms |
IBI 354; IBI354
Click to Show/Hide
|
|||||
| Organization |
Innovent Biologics (Suzhou) Co. Ltd.
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Indication |
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
DX-8951 derivative (DXd)
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
PODS-CHX-A"-DTPA
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the glycan remodeling and click chemistry at Asn297.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.